Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.68 |
| ▸ | HTT | P42858 | 1/20 | 0.68 |
| ▸ | GAA | P10253 | 1/20 | 0.64 |
| ▸ | HPGD | P15428 | 1/20 | 0.64 |
| ▸ | POLB | P06746 | 2/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | GLA | P06280 | 1/20 | 0.57 |
| ▸ | USP2 | O75604 | 1/20 | 0.57 |
| ▸ | PLAU | P00749 | 1/20 | 0.57 |
| ▸ | HPN | P05981 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2636629 | 1.00 | ALDH1A1 (0.68) | ALDH1A1HTTGAAHPGDPOLB | |
| SCHEMBL696506 | 1.00 | ALDH1A1 (0.68) | ALDH1A1HTTGAAHPGDPOLB | |
| Hydrochloric Acid SCHEMBL4077466 | 0.98 | ALDH1A1 (0.67) | ALDH1A1HTTGAAHPGDPOLB | |
| Water SCHEMBL5497101 | 0.98 | ALDH1A1 (0.67) | ALDH1A1HTTGAAHPGDPOLB | |
| Hydrochloric Acid SCHEMBL4077465 | 0.98 | ALDH1A1 (0.67) | ALDH1A1HTTGAAHPGDPOLB | |
| SCHEMBL6302459 | 0.96 | ALDH1A1 (0.64) | ALDH1A1HTTGAAHPGDPOLB | |
| SCHEMBL5702221 | 0.92 | ALDH1A1 (0.62) | ALDH1A1HTTGAAHPGDPOLB | |
| SCHEMBL5702094 | 0.92 | ALDH1A1 (0.62) | ALDH1A1HTTGAAHPGDPOLB | |
| SCHEMBL4669530 | 0.92 | ALDH1A1 (0.62) | ALDH1A1HTTGAAHPGDPOLB | |
| SCHEMBL8446614 | 0.92 | MMP2 (0.63) | ALDH1A1HTTGAAHPGDPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015102024-A2 | NOVEL SUBSTITUTED 5 MEMBERED HETEROCYCLIC COMPOUNDS AND PREPARATION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2015-07-09 | — | — | WO | claimed |
| US-7045629-B2 | Method for producing-2[-5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane | MERCK PATENT GMBH (DE) | 2006-05-16 | — | — | US | claimed |
| EP-1383763-B1 | METHOD FOR PRODUCING 2-(-5-(4-FLUOROPHENYL)-3-PYRIDYLMETHYLAMINOMETHYL)-CHROMANE | MERCK PATENT GMBH (DE) | 2005-10-12 | — | — | EP | claimed |
| US-20040138266-A1 | Method for producing-2[-5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane | MERCK PATENT GMBH (DE) | 2004-07-15 | — | — | US | claimed |
| EP-0420120-B1 | Optically active benzyl alcohol compound and pharmaceutical composition | HOKURIKU PHARMACEUTICAL (JP) | 1994-08-31 | — | — | EP | claimed |
| EP-0220601-B1 | PYRANOINDOLIZINE DERIVATIVES AND PREPARATION PROCESS THEREOF | DAIICHI SEIYAKU CO., LTD. (JP) | 1991-12-11 | — | — | EP | claimed |
| EP-0420120-A2 | Optically active benzyl alcohol compound and pharmaceutical composition | HOKURIKU PHARMACEUTICAL CO., LTD. (JP) | 1991-04-03 | — | — | EP | claimed |
| EP-0220601-A1 | Pyranoindolizine derivatives and preparation process thereof | DAIICHI SEIYAKU CO., LTD. (JP) | 1987-05-06 | — | — | EP | claimed |
| JP-10036327-A | — | — | None | — | — | JP | disclosed |
| JP-9286763-A | — | — | None | — | — | JP | disclosed |
| JP-7285966-A | — | — | None | — | — | JP | disclosed |
| US-20260001873-A1 | NOVEL INHIBITORS | VIVORYON THERAPEUTICS N.V. (DE) | 2026-01-01 | — | — | US | disclosed |
| US-12384772-B2 | Inhibitors | VIVORYON THERAPEUTICS N.V. (DE) | 2025-08-12 | — | — | US | disclosed |
| CN-117024352-A | Novel inhibitors | 维沃里翁治疗股份有限公司 | 2023-11-10 | — | — | CN | disclosed |
| EP-0220601-B1 | PYRANOINDOLIZINE DERIVATIVES AND PREPARATION PROCESS THEREOF | DAIICHI SEIYAKU CO., LTD. (JP) | 1991-12-11 | — | — | EP | disclosed |
| US-4971990-A | HYPOTENSIVE AGENTS, DYSUREA | HOKURIKU PHARMACEUTICAL CO., LTD. (JP) | 1990-11-20 | — | — | US | disclosed |
| EP-0331943-A1 | Phenoxyethylamine derivatives, process for preparing the same, and composition for exhibiting excellent alpha-1-blocking activity containing the same | Hokuriku Pharmaceutical Co.,Ltd (JP) | 1989-09-13 | — | — | EP | disclosed |
| US-4778891-A | Certain pyrano (3,4-f)-indolizine derivatives | DAIICHI SEIYAKU CO., LTD. (JP) | 1988-10-18 | — | — | US | disclosed |
| EP-0220601-A1 | Pyranoindolizine derivatives and preparation process thereof | DAIICHI SEIYAKU CO., LTD. (JP) | 1987-05-06 | — | — | EP | disclosed |
| US-4596819-A | Antidepressive agents | WARNER-LAMBERT COMPANY (US) | 1986-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260001873-A1 | NOVEL INHIBITORS | GLS, GLS2, SULT1E1 | ALDH1A1 1183/4885HTT 1548/4885GAA 674/4885 |
| US-20040138266-A1 | Method for producing-2[-5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane | PAH, HPD, CYP3A43 | ALDH1A1 263/4885HTT 3941/4885GAA 1269/4885 |
| US-12384772-B2 | Inhibitors | GLS, QPCT, GLS2 | ALDH1A1 1415/4885HTT 1025/4885GAA 171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.